牛磺熊去氧胆酸(TUDCA)作为肌萎缩侧索硬化(ALS)患者附加治疗的安全性和有效性随机双盲临床试验:TUDCA-ALS试验的统计分析计划
TUDCA-ALS试验是一项双盲、平行组、安慰剂对照、随机多中心III期试验,评估TUDCA作为利鲁唑附加治疗在ALS患者中的疗效和安全性。主要终点为随机治疗期(18个月)与导入期(3个月)相比ALSFRS-R斜率改善至少20%的治疗反应。患者招募于2019年2月22日开始,2021年12月23日结束,数据库将于2023年9月锁定。
要点
- TUDCA-ALS试验为双盲、平行组、安慰剂对照、随机多中心III期试验,评估TUDCA作为利鲁唑附加治疗。
- 主要终点为随机治疗期(18个月)与导入期(3个月)相比ALSFRS-R斜率改善至少20%的治疗反应。
- 随机化按国家分层,主要分析基于意向性治疗原则采用未调整逻辑回归模型。
核心结论
- 该试验旨在确定TUDCA是否能有效减缓ALS患者的疾病进展,重点关注具有临床意义且稳健的结局。
研究设计与样本
- TUDCA-ALS研究是一项双盲、平行组、安慰剂对照、随机多中心III期试验,评估TUDCA作为利鲁唑附加治疗在ALS患者中的疗效和安全性。
- 患者招募于2019年2月22日开始,于2021年12月23日结束,数据库将于2023年9月锁定。
- 随机化按国家分层,主要分析基于意向性治疗原则采用未调整逻辑回归模型。
关键数值与推荐
- 主要结局指标为治疗反应,定义为随机治疗期(18个月)与导入期(3个月)相比ALSFRS-R斜率改善至少20%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a highly debilitating neurodegenerative condition. Despite recent advancements in understanding the molecular mechanisms underlying ALS, there have been no significant improvements in therapeutic options for ALS patients in recent years. Currently, there is no cure for ALS, and the only approved treatment in Europe is riluzole, which has been shown to slow the disease progression and prolong survival by approximately 3 months. Recently, tauroursodeoxycholic acid (TUDCA) has emerged as a promising and effective treatment for neurodegenerative diseases due to its neuroprotective activities. METHODS: The ongoing TUDCA-ALS study is a double-blinded, parallel arms, placebo-controlled, randomized multicenter phase III trial with the aim to assess the efficacy and safety of TUDCA as add-on therapy to riluzole in patients with ALS. The primary outcome measure is the treatment response defined as a minimum of 20% improvement in the ALS Functional Rating Scale-Revised (ALSFRS-R) slope during the randomized treatment period (18 months) compared to the lead-in period (3 months). Randomization will be stratified by country. Primary analysis will be conducted based on the intention-to-treat principle through an unadjusted logistic regression model. Patient recruitment commenced on February 22, 2019, and was closed on December 23, 2021. The database will be locked in September 2023. DISCUSSION: This paper provides a comprehensive description of the statistical analysis plan in order to ensure the reproducibility of the analysis and avoid selective reporting of outcomes and data-driven analysis. Sensitivity analyses have been included in the protocol to assess the impact of intercurrent events related to the coronavirus disease 2019. By focusing on clinically meaningful and robust outcomes, this trial aims to determine whether TUDCA can be effective in slowing the disease progression in patients with ALS. TRIAL REGISTRATION: ClinicalTrials.gov NCT03800524 . Registered on January 11, 2019.
引用
- Lombardo FL, Spila Alegiani S, Mayer F, et al. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial. Trials. 2023. PMID: 38053196. doi:10.1186/s13063-023-07638-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。